The endothelial lining of the blood-brain barrier tightly controls the distribution of peptide hormones between the central nervous system and the circulation. Using primary cultures of brain microvessel endothelial cells, an in vitro model of the blood-brain barrier, we report here the uptake and transport of the octapeptide angiotensin II by a specific receptor population. Using the angiotensin II antagonists losartan (AT 1 specific) and PD 123,319 (AT 2 specific) we have shown that both the uptake and transport of angiotensin II were mediated by the AT 1 receptor. Western blot analysis confirmed the existence of the AT 1 receptor in our cell culture model. Rhodamine 123 studies also suggested that both angiotensin II antagonists, but not angiotensin II, were substrates for the P-glycoprotein efflux system thus restricting the transport of these compounds. These results suggest an AT 1 receptor mediates uptake and transport of angiotensin II at the blood-brain barrier and may contribute to the regulation of cerebrovascular levels of the peptide.
Introduction
The octapeptide angiotensin II produces a number of physiological actions, the most common of these being its peripheral role as a potent vasoconstrictor (1) . The renin angiotensin system is also known to exist in the brain (1) (2) (3) . Brain angiotensin II appears to function in the central This is a non-final version of an article published in final form in "Rose, J.M. and Audus, K.L. (1999) AT1 receptors mediate angiotensin II uptake and transport by brain microvessel endothelial cells in primary culture. J. Cardiovasc. Pharmacol. 33, [30] [31] [32] [33] [34] [35] . PMID: 9890393." Publisher's official version: <http://journals.lww.com/cardiovascularpharm/pages/articleviewer.aspx?year=1999&issue=01000&article=00005&type=abstr act> . Open Access version: http://kuscholarworks.ku.edu/dspace/. 3 regulation of blood pressure, the regulation of body fluid volume, and the control of hormone release (4) . Angiotensin II does not readily penetrate the blood-brain barrier (BBB) and the effects of angiotensin II are generally considered to be mediated by receptors in the circumventricular regions of the brain which lack the BBB. Speth and Harik (5) and Grammas et al. (6) observed that there were angiotensin II receptor binding sites on the brain microvessel endothelial cells (BMECs) lining the BBB and that these binding sites have biological activity (7, 8) . Subsequently, studies by Guillot and Audus reported that there were specific angiotensin II binding sites on BMECs in primary culture and that the cells internalized the peptide (9) . Angiotensin II receptors are also found on peripheral vascular endothelial cells and mediate transendothelial transport of the peptide (10) . The subtyping of these binding sites, however, has not been reported.
There are two major subtypes of angiotensin II receptors known to exist, designated AT 1 and AT 2 . Both receptor subtypes have been found in brain tissue of rats, monkeys, and humans.
Most of the known actions of angiotensin II are mediated through the AT 1 receptor (11). The development of nonpeptide antagonists has made it possible to distinguish between the two receptor subtypes. Losartan is a highly specific nonpeptide AT 1 antagonist and PD 123,319 is a highly specific nonpeptide AT 2 antagonist. These antagonists lack the partial agonist activities of peptide angiotensin II analogs, allowing study of angiotensin II processing without interfering side effects (11) .
The objective of this study was to use primary cultures of BMECs to reveal the receptor subtype populations that regulate angiotensin II uptake and distribution across the BBB. The This is a non-final version of an article published in final form in "Rose, J.M. and Audus, K.L. (1999) AT1 receptors mediate angiotensin II uptake and transport by brain microvessel endothelial cells in primary culture. J. Cardiovasc. Pharmacol. 33, 30-35. PMID: 9890393." Publisher's official version: <http://journals.lww.com/cardiovascularpharm/pages/articleviewer.aspx?year=1999&issue=01000&article=00005&type=abstr act> . Open Access version: http://kuscholarworks.ku.edu/dspace/. 4 nonpeptide antagonists losartan and PD 123,319 were used in this study to distinguish the AT 1 and AT 2 receptor subtypes on BMECs. The definition of receptor subtypes providing for the clearance of peptides at the BBB contributes to our knowledge of fundamental physiological mechanisms regulating cerebrovascular levels of vasoeffectors. In addition, characterization of BBB carrier mechanisms potentially can provide physiological strategies to beneficially circumvent this barrier by covalently linking pharmacophores to receptor ligands known to be transported across the barrier (12) . Ham nutrient mixture (Gibco Life Technologies, Grand Island, NY), 10 mM HEPES, pH 7.4, 13 mM sodium bicarbonate, 10 % plasma-derived equine serum, 100 µg/ml heparin, 100 µg/ml streptomycin, 100 µg/ml penicillin G, 50 µg/ml polymyxin B, and 2.5 µg/ml amphotericin B (Sigma Chemical Co.). The cells were cultured at 37°C with 95 % humidity and 5 % CO 2 . Cells were fed on the third day after seeding and then every two days until confluent monolayers were formed (10-14 days). Rhodamine 123 uptake studies were also performed on confluent monolayers in 12-well plates.
Materials and methods

Materials
Binding and internalization studies
Angiotensin II, losartan, PD 123,319, or cyclosporin A dissolved in culture medium was added to each well and the plate was preincubated for one hour at 37°C. After the one hour preincubation, rhodamine 123 was added to each well for a final concentration of 5 µM, and the plate was incubated at 37°C for an additional hour. After the second incubation, the plate was rinsed and the monolayers were solubilized as described above. The contents of each well were collected into cuvettes and assayed by fluorescence using an SLM-Aminco 4800 fluorometer (ex = 500 nm, em = 550 nm). After measuring relative fluorescence, 100 µl was removed from each cuvette and assayed for protein content with the BCA protein assay kit (Pierce).
Transendothelial permeability studies
Polycarbonate membranes (pore size 0.4 µm) were placed into 100 mm tissue culture dishes and coated with rat-tail collagen and bovine fibronectin. BMECs were grown to confluent monolayers as determined by inspection of the areas around the membranes using an inverted microscope. The basolateral side of the cells was defined as the side facing the collagen matrix.
Once confluent monolayers were formed, the membranes were carefully placed into a horizontal Side-bi-Side diffusion apparatus (Crown Glass, Inc., Somerville, NJ) for transendothelial permeability studies. The area of the diffusion membrane was 0.636 cm 2 . The donor and receiver chambers were filled with 3.0 ml culture medium, containing equine serum, and the temperature was maintained at 37°C with an external circulating water bath. The contents of each chamber were stirred with Teflon coated magnetic stir bars at a speed of 600
This is a non-final version of an article published in final form in "Rose, J.M. After each receiver sample, the volume was replaced with fresh medium. The samples were placed in a scintillation vial with 10 ml of scintillation cocktail and assayed by scintillation spectrometry. The flux was determined by plotting pmoles vs. minutes for each sampling interval (0-30 minutes and 30-90 minutes). The apparent permeability coefficient was calculated using the equation:
where flux is the slope of each line, A is the area of the membrane, and C Do is the initial donor concentration. The donor concentration did not change by more than 10 % during the time period of these experiments.
Western blot
Total cellular extract was prepared using confluent monolayers of BMECs. The cells were lysed with a 45 min incubation in ice-cold phosphate buffer saline containing 3 % sodium dodecyl sulfate (SDS) and protease inhibitors (0.1mM leupeptin, 73 µM pepstatin A, and 100 µg/ml PMSF). The cell lysate was then centrifuged at 12,000 g for 15 min and the supernatant containing solubilized membrane proteins was stored at -20°C and used for further analysis.
This is a non-final version of an article published in final form in "Rose, J.M. Total cell protein was measured by the Micro BCA protein assay (Pierce) using bovine serum albumin as a standard. Cell plasma membranes were prepared using confluent monolayers of
BMECs. The cells were removed from the tissue culture plates with a trypsin / EDTA solution.
The cell suspension was then diluted in 5 volumes of ice-cold 10 mM Tris -HCl, 0.1 mM EDTA, pH 7.5 (TE buffer) and homogenized. The homogenate was passed through a fine-gauge syringe needle and then centrifuged at 500 g for 15 minutes to pellet unbroken cells and nuclei, leaving a membrane containing supernatant. The plasma membranes were collected by centrifugation at 40,000 g for 60 minutes. The pellets were washed in 10 volumes of TE buffer and re-centrifuged at 40,000 g for 60 minutes. The pellets were resuspended in TE buffer and stored at -70°C (19) . The protein concentration was measured by the Micro BCA protein assay (Pierce) using bovine serum albumin as a standard. Cell proteins were electrophoresed on a 10 % Tris-Glycine gel (NOVEX, San Diego, CA) and transferred to a PVDF membrane.
Immunoreactive protein was detected with the AT 1 polyclonal antibody using the enhanced chemiluminescence method (ECL) as per the manufacturer's protocol (Amersham, Downers Grove, IL). A positive control peptide (Santa Cruz Biotechnology, Inc.) and a negative control (serum albumin) were used to establish and confirm blot conditions.
Statistical analysis
The comparison between mean values within each experimental series was performed by oneway analysis of variance using Dunnett's test to compare several treatments against a control.
Results
This The temperature and concentration dependence of the binding and internalization kinetics for angiotensin II were described in an earlier report (9) . In this study, the uptake of Western blot studies, shown in Fig. 7A and 7B, were generated using an AT 1 receptor polyclonal antibody and show that the AT 1 receptor is present in BMECs. 
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In this study, we have shown that the binding and uptake of angiotensin II by BMECs was inhibited by losartan, the AT 1 receptor antagonist and not the AT 2 antagonist, PD 123,319. This observation was consistent with the presence of a single population of angiotensin II binding sites that were described by Guillot and Audus (9) . Therefore, it appears that an AT 1 receptor mediates clearance of angiotensin II by BMECs. Although our data includes both binding and internalization, the concentrations at which an antagonist was inhibitory were higher than expected based on other receptor studies (11) and our observation that specific binding of angiotensin II to bovine BMECs could be inhibited by nM concentrations of peptide analogs, saralasin and sarathrin (9).
Our earlier studies on the uptake and transport of losartan itself indicated that the compound was an apparent substrate for P-glycoprotein at submicromolar concentrations (20).
Therefore, P-glycoprotein may be a competing mechanism for losartan interactions with the BMEC membrane. To determine if the antagonists and angiotensin II were potential substrates for P-glycoprotein, the uptake studies were performed with rhodamine 123, a specific substrate for the P-glycoprotein efflux pump (23) (24) (25) (26) . The uptake of rhodamine 123 alone and with pretreatment of the monolayers using angiotensin II, losartan, PD 123,319, or a positive control, cyclosporin A (26), suggested that both antagonists were inhibitors of P-glycoprotein.
Angiotensin II does not affect rhodamine 123 uptake, therefore it appears that the nonpeptide antagonists may not be as effective in blocking BMEC uptake and binding due to their added affinity for P-glycoprotein. On the other hand, the micromolar concentrations used here remain within the concentration range of losartan antagonist activity across a variety of different species, tissue types, and angiotensin II mediated biological functions (27) .
This is a non-final version of an article published in final form in "Rose, J.M. 
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Angiotensin II was previously shown to be transported across arterial endothelial cell monolayers by a specific, saturable mechanism that could be inhibited by unlabeled peptide.
Mineo et al. required micromolar concentrations of angiotensin to inhibit arterial endothelial cell transport of the radiolabeled angiotensin II (10) . We have observed that angiotensin II crosses monolayers of BMECs intact (28, 29) at a rate slightly higher than expected based on its molecular weight. The transport was also a saturable process, K m 1.7 nM, and angiotensin II transport from the apical to the basolateral side was greater than the reverse direction (28, 30) .
In the present study, the differential effects of the two angiotensin II receptor antagonists on the passage of the peptide through monolayers of BMECs affirmed the role of an AT 1 mediated mechanism with losartan inhibiting the transport of angiotensin II. As observed in the uptake studies, the AT 2 antagonist effect on angiotensin II transport was also absent. Consistent with the uptake studies, micromolar concentrations of losartan were required to inhibit angiotensin transport.
The AT 1 receptor belongs to the class of G-protein-coupled seven-transmembrane receptors and is made up of 359 amino acids with an unmodified molecular weight of 41,000 (11 angiotensin II distribution in the cerebrovasculature. This observation appears consistent with the local control of the renin-angiotensin systems associated with specific tissues (1-3) .
Alternatively, the AT 1 receptors might provide a mechanism that could be exploited for facilitating delivery of some substances via chimeric constructs into the central nervous system like other endogenous peptides, insulin and transferrin (35, 36) . However, like insulin, it is also apparent that angiotensin II has significant biological activity at the BBB, regulating the BMEC secretion of other vasoeffectors (9,21,22,37) and the permeability properties of the cells (7-9)
that would preclude its use in chimeric constructs. The nonpeptide antagonists such as losartan could provide alternative targeting ligands in a chimeric construct; unfortunately, losartan appears to be a substrate for BMEC efflux mechanisms (20). Therefore, future works in our laboratory will focus on the transport of alternative ligands for the carrier, including metabolically stable angiotensin II peptide analogs.
In summary, we have shown that the uptake and transport of angiotensin II by BMECs appears to be mediated by the AT 1 receptor. These results form a better understanding of the regulation of cerebrovascular levels of angiotensin II by the BBB and may lead to possible delivery strategies for therapeutic chimeric peptides. 
